Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian
tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard
chemotherapy with the possibility of crossover at the time of progression.